First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs

First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study

Novel treatment targets 6M annual dog diarrhea cases with no current FDA-approved options. Partnership discussions underway for expanded market access. Learn more.